Stock Track | Kiniksa Pharmaceuticals Plummets 9.79% Intraday on Significant Q4 Earnings Miss

Stock Track02-24

Kiniksa Pharmaceuticals Ltd. (KNSA) experienced a sharp intraday decline of 9.79% on Tuesday, as investors reacted negatively to the company's latest financial results.

The stock's significant drop appears to be primarily driven by a substantial earnings miss. Kiniksa reported fourth-quarter earnings per share of $0.17, which fell well below analyst consensus estimates ranging from $0.33 to $0.38. This represents a miss of approximately 54.67% compared to the $0.38 estimate, according to one analysis.

While the company's quarterly sales of $202.127 million exceeded expectations, the disappointing bottom-line performance overshadowed the revenue beat. Concurrently, Kiniksa provided 2026 net product revenue guidance for its key product Arcalyst, projecting between $900 million and $920 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170098144?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170098144","market":"hk","top_or_hot":-1,"title":"Stock Track | Kiniksa Pharmaceuticals Plummets 9.79% Intraday on Significant Q4 Earnings Miss","media":"Stock Track","content":"<p>Kiniksa Pharmaceuticals Ltd. (KNSA) experienced a sharp intraday decline of 9.79% on Tuesday, as investors reacted negatively to the company's latest financial results.</p><p>The stock's significant drop appears to be primarily driven by a substantial earnings miss. Kiniksa reported fourth-quarter earnings per share of $0.17, which fell well below analyst consensus estimates ranging from $0.33 to $0.38. This represents a miss of approximately 54.67% compared to the $0.38 estimate, according to one analysis.</p><p>While the company's quarterly sales of $202.127 million exceeded expectations, the disappointing bottom-line performance overshadowed the revenue beat. Concurrently, Kiniksa provided 2026 net product revenue guidance for its key product Arcalyst, projecting between $900 million and $920 million.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kiniksa Pharmaceuticals Plummets 9.79% Intraday on Significant Q4 Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kiniksa Pharmaceuticals Plummets 9.79% Intraday on Significant Q4 Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kiniksa Pharmaceuticals Ltd. (KNSA) experienced a sharp intraday decline of 9.79% on Tuesday, as investors reacted negatively to the company's latest financial results.</p><p>The stock's significant drop appears to be primarily driven by a substantial earnings miss. Kiniksa reported fourth-quarter earnings per share of $0.17, which fell well below analyst consensus estimates ranging from $0.33 to $0.38. This represents a miss of approximately 54.67% compared to the $0.38 estimate, according to one analysis.</p><p>While the company's quarterly sales of $202.127 million exceeded expectations, the disappointing bottom-line performance overshadowed the revenue beat. Concurrently, Kiniksa provided 2026 net product revenue guidance for its key product Arcalyst, projecting between $900 million and $920 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNSA","symbol_name":"Kiniksa Pharmaceuticals Ltd.","start_time":0,"source_url":"","article_id":"1170098144","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170098144","pubTimestamp":1771943989,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Kiniksa Pharmaceuticals Ltd. (KNSA) experienced a sharp intraday decline of 9.79% on Tuesday, as investors reacted negatively to the company's latest financial results.The stock's significant drop...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"个股追踪|Kiniksa Pharmaceuticals盘中暴跌9.79%因Q4盈利大幅未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":1},"content_text":"Kiniksa Pharmaceuticals Ltd. (KNSA) experienced a sharp intraday decline of 9.79% on Tuesday, as investors reacted negatively to the company's latest financial results.The stock's significant drop appears to be primarily driven by a substantial earnings miss. Kiniksa reported fourth-quarter earnings per share of $0.17, which fell well below analyst consensus estimates ranging from $0.33 to $0.38. This represents a miss of approximately 54.67% compared to the $0.38 estimate, according to one analysis.While the company's quarterly sales of $202.127 million exceeded expectations, the disappointing bottom-line performance overshadowed the revenue beat. Concurrently, Kiniksa provided 2026 net product revenue guidance for its key product Arcalyst, projecting between $900 million and $920 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170098144","isCrawlerRequest":true}